SHAREHOLDER ALERT: Investigation on Behalf of Boston Scientific Corporation Investors Announced by Law Offices of Howard G. Smith

Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE:BSX). The investigation concerns possible violations of federal securities laws and focuses on certain statements issued by Boston Scientific concerning the Company’s business and operations.

Boston Scientific develops, manufactures and markets medical devices, including coronary stent systems and other interventional cardiology products, for use in various interventional medical specialties worldwide. The investigation is related to the Company’s August 6, 2014, disclosure that on July 11, 2014, the Company was served with a subpoena from the U.S. Attorney for the District of New Jersey, in connection with BridgePoint Medical, Inc., which Boston Scientific acquired in October 2012. According to the Company, the subpoena seeks information related to the BridgePoint Medical acquisition “including information relating to its sale of CrossBoss and Stingray products, [and] educational and training activities that relate to those sales.”

If you purchased Boston Scientific securities, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at 215-638-4847, Toll-Free at 888-638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

Contacts:

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.